Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul;20(7):399-400.
doi: 10.1038/s41577-020-0358-6.

COVID-19 vaccines: neutralizing antibodies and the alum advantage

Peter J Hotez  1   2   3   4 , David B Corry  5   6 , Ulrich Strych  7   8 , Maria Elena Bottazzi  9   10   11
Affiliations

COVID-19 vaccines: neutralizing antibodies and the alum advantage

Peter J Hotez et al. Nat Rev Immunol. 2020 Jul.

Abstract

Achieving high levels of neutralizing antibodies to the spike protein of SARS-CoV-2 in a safe manner is likely to be crucial for an effective vaccine. Here, we propose that aluminium-based adjuvants might hold the key to this.

PubMed Disclaimer

Conflict of interest statement

P.J.H. and M.E.B. are investigators leading the development of coronavirus vaccines against SARS-CoV, MERS-CoV and SARS-CoV-2. D.B.C. is a scientific advisor and holds intellectual property in Atropos Therapeutics, LLC. U.S. declares no competing interests.

References

    1. Yu J, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020 doi: 10.1126/science.abc6284. - DOI - PMC - PubMed
    1. Gao Q, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020 doi: 10.1126/science.abc1932. - DOI - PMC - PubMed
    1. Chen W-H, et al. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with alum induces protective immunity and reduces immune enhancement. bioRxiv. 2020 doi: 10.1101/2020.05.15.098079. - DOI - PMC - PubMed
    1. van Doremalen N, et al. ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. bioRxiv. 2020 doi: 10.1101/2020.05.13.093195. - DOI - PubMed
    1. Zhu F-C, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020 doi: 10.1016/S0140-6736(20)31208-3. - DOI - PMC - PubMed